CN101306091A - Use of prince feather and fleabane combination in preparing medicament for treating kidney disease - Google Patents
Use of prince feather and fleabane combination in preparing medicament for treating kidney disease Download PDFInfo
- Publication number
- CN101306091A CN101306091A CNA2008103025306A CN200810302530A CN101306091A CN 101306091 A CN101306091 A CN 101306091A CN A2008103025306 A CNA2008103025306 A CN A2008103025306A CN 200810302530 A CN200810302530 A CN 200810302530A CN 101306091 A CN101306091 A CN 101306091A
- Authority
- CN
- China
- Prior art keywords
- polygoni orientalis
- herba polygoni
- medicine
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the application of the combination of prince feather and fleabane in preparing medicaments for curing kidney diseases. The kidney diseases include nephritis, nephropathy syndrome, chronic renal failure, diabetes, nephropathy, chronic glomerulonephritis and so on. The combination of prince feather and fleabane is prepared as follows: Chinese traditional medicaments, namely prince feather and fleabane, are combined; the combined prince feather and fleaban are extracted, or the prince feather and the fleabane are extracted separately. The invention provides a new medicinal use of the combination of prince feather and fleabane, namely the application of the combination in preparing medicaments for curing kidney diseases. Proven through animal experiments, the combination of the prince feather and the fleabane has true curative effect on cure of kidney diseases, and provides a new medicine for curing kidney diseases and a new option for sufferers.
Description
Technical field
The present invention relates to the application of compositions in the preparation medicine, particularly relate to the application in preparation treatment kidney disease medicine of Herba Polygoni Orientalis and erigeron breviscapus composition.
Background technology
Kidney is the important component part of urinary system, the sick urinary function that at first influences of kidney.Doctor trained in Western medicine also has endocrine function except that thinking that kidney is the urinary organs, if can secrete erythropoietin, can secrete feritin, can promote the conversion of calcitriol, and human body is had crucial effect.The traditional Chinese medical science thinks that kidney not only urinates, and more has main bone to give birth to human skull, and the function of main reproduction is controlled the part reproductive system disease and reach good result from the kidney opinion usually.Kidney disease sickness rate height, the disability rate height causes serious threat to the people's health.
Chronic renal failure (abbreviation chronic kidney hypofunction) claims chronic renal insufficiency again, be meant the chronic progressive external excess of the kidney matter infringement that a variety of causes causes, cause the obvious atrophy of kidney, can not keep its basic function, clinical manifestation is the metabolite retention, water, electrolyte, acid base imbalance, each system of whole body gets involved, and is also referred to as uremia.This disease annual morbidity accounts for nature crowd's 50-200 people/1,000,000, and prognosis is serious.The sickness rate of chronic kidney hypofunction accounts for 3/10000ths to five of total population.Beijing's statistics in 1962 is died from the kidney patient every year and is about 96 people/million people's mouth.The First Hospital Affiliated to Beijing Medical College once added up in 1 year of year October in October, 1973 to 1974, and the routine number of uremic death accounts for 13% of internal medicine death.Nineteen eighty-three, Guiyang Medical College was added up, and the chronic kidney hypofunction patient accounts for 26% of internal medicine inpatient, is first in the internal medicine death.Every year is died from the chronic kidney hypofunction in the area, Kweiyang, and the person is about 32 people/million people's mouth.Britain's statistics, in every million people's mouth, annual children's 3～5 people die from renal failure.The M ﹠ M that this shows chronic kidney hypofunction is all high, and the patient's age section mostly be in, the youth, the health that seriously endangers broad masses of the people is given ten million family's Jonah, also has a strong impact on social productive forces simultaneously.
Chronic glomerulonephritis is called for short chronic nephritis, is by the group leader's course of disease (to many decades) due to the multiple primary glomerulopathy, is the disease of clinical manifestation with albuminuria, edema, hypertension.The gradual chronic renal failure of final multiple generate.
Acute glomerulonephritis is called for short acute nephritis, it is a kind of commonly encountered diseases, mean that one group of cause of disease and pathogeny differ, but the last table of clinical process doctor now is an Acute onset, with hematuria, albuminuria, edema, hypertension and glomerular filtration rate drop to the renal glomerular disease deputy director of characteristics, so also often be called the outstanding syndrome of acute nephritis.After majority occurs in infection on the clinical center, especially behind the hemolytic streptococcal infection, also be found in other infection.Be modal a kind of nephropathy in children's's period, the age, rare below 2 years old, M-F was about 2: 1 more to see 3～8 years old.
Pyelonephritis is meant the renal pelvis that is caused by pathogenic infection, the inflammation of renal calices amount of money excess of the kidney matter, is the commonly encountered diseases of urinary tract infection.General companion's lower urinary tract inflammation is difficult for strict the differentiation clinically.Be mainly in 20-40 year women (men and women fall ill than be 1: 10).Can be divided into acute and chronic two phase chronic pyelonephritiss according to clinical disease course and disease pyelonephritis is the major reasons that cause chronic renal insufficiency.
(nephrotic syndrome NS) is one group of clinical syndrome in the renal glomerular disease to the nephrotic syndrome, and it is not the independence disease.Also being a kind of common department of pediatrics kidney disease, is because Different types of etiopathogenises causes tight bead basement membrane permeability to increase, the clinical syndrome that a large amount of albumen are lost from urine.The typical case shows as a large amount of albuminuria (every day＞3.5g/1.73m2 body surface area), hypoproteinemia (plasma albumin＜30g/L), edema companion or without hyperlipemia, diagnostic criteria should be a large amount of albuminuria and hypoproteinemia.Can be divided into constitutional and Secondary cases nephrotic syndrome according to its clinical manifestation.
Herba Polygoni Orientalis and erigeron breviscapus composition mainly are made up of Herba Polygoni Orientalis and Herba Erigerontis two flavor medicines.Wherein Herba Polygoni Orientalis is the herb or the whole herb with root of polygonaceae plant smartweed, has expelling wind and removing dampness, and the effect of promoting blood circulation and stopping pain can be used for increasing the heart coronary flow, slows down the oxygen consumption, resists myocardial ischemia bronchospasm etc.; Herba Erigerontis is the dry herb of feverfew Erigeron breviscapus (Vant.) Hand.-Mazz., has the cold expelling of inducing sweat, relaxing muscles and tendons to promote blood circulation, the effect of pain relieving removing food stagnancy has antithrombotic, microcirculation improvement, resists myocardial ischemia, cerebral ischemia, improves renal function, anti-hepatic fibrosis, improves pharmacological actions widely such as renal function.Both share the effect of oxygen consumptions such as more can strengthening the resisting coronary heart disease angina pectoris, ischemia aspect heart disease.The present patent application people's the patent No. is that to be called the patent of invention of " treatment angina pectoris Chinese medicine preparation and preparation method thereof " and number of patent application be that application for a patent for invention that CN200610051009.0, name are called " a kind of Chinese medicine preparation for the treatment of angina pectoris and preparation method thereof " discloses Chinese medicine preparation with the treatment angina pectoris of Herba Polygoni Orientalis and Herba Erigerontis preparation and preparation method thereof for CN02128066.5, name.The applicant has found unexpectedly also that in research subsequently Herba Polygoni Orientalis and erigeron breviscapus composition also have definite curative effect aspect the treatment other diseases.
Summary of the invention
Technical problem to be solved by this invention provides second medical usage of a kind of Herba Polygoni Orientalis and erigeron breviscapus composition, i.e. its application in preparation treatment kidney disease medicine.
In order to solve the problems of the technologies described above, the present invention adopts following technical scheme:
The application in preparation treatment kidney disease medicine of Herba Polygoni Orientalis and erigeron breviscapus composition.
The application in preparation treatment nephritis medicine of Herba Polygoni Orientalis and erigeron breviscapus composition.
The application in preparation treatment nephrotic syndrome medicine of Herba Polygoni Orientalis and erigeron breviscapus composition.
The application in preparation treatment chronic renal failure medicine of Herba Polygoni Orientalis and erigeron breviscapus composition.
The application in preparation treatment medicine for treating diabetic nephropathy of Herba Polygoni Orientalis and erigeron breviscapus composition.
The application in preparation treatment chronic glomerulonephritis medicine of Herba Polygoni Orientalis and erigeron breviscapus composition.
Aforementioned Herba Polygoni Orientalis and erigeron breviscapus composition are in the application of preparation in the medicine: described Herba Polygoni Orientalis and erigeron breviscapus composition merge the back by raw material of Chinese medicine Herba Polygoni Orientalis and Herba Erigerontis and extract the extract of gained or extract the extract that the back merges gained respectively and form.
According to listed as parts by weight, above-mentioned Herba Polygoni Orientalis and erigeron breviscapus composition are to be prepared from through extraction for 1～10 part by 1～10 part of raw material of Chinese medicine Herba Polygoni Orientalis and Herba Erigerontis.
Aforesaid medicine is ejection preparation, tablet, pill, capsule, granule, suspending agent or Emulsion.
Described medicine is preferably ejection preparation.
Herba Polygoni Orientalis and erigeron breviscapus composition can be that the method for the merging decoction described in 02128066.5, precipitate with ethanol, resin isolation is extracted according to the patent No., can be that the method for the independent extraction separation described in 200610051009.0 is extracted also, can also extract with the method for routine according to number of patent application.
Among the present invention: Herba Polygoni Orientalis has diffusing blood, removing food stagnancy, analgesic function, mainly contains compositions such as flavonoid orientin, orientoside, phylloquinone, can be used for rheumatic arthritis, myocardial ischemia, blood pressure lowering, the bullate treatment of tinea pedis, is principal agent; Herba Erigerontis has expelling cold and relieving exterior syndrome, relaxing muscles and tendons to promote blood circulation, and the function of pain relieving removing food stagnancy is used for paralysis, rheumatic arthralgia, stomachache, toothache, acute renal failure, injury from falling down etc., is accessory drugs.The present invention has carried out a series of test in development process, better understand the present invention in order to make those of ordinary skills, below reaches composition, the Preparation Method And The Use that embodiment further sets forth compound oriental smartweed preparation of the present invention by experiment:
One, the preparation of medicine
Raw material: Herba Polygoni Orientalis 7500g, Herba Erigerontis 1500g
Preparation method: get Herba Polygoni Orientalis and add 10 times of decoctings and boil 3 times, each 1 hour, filter, merging filtrate, concentrating under reduced pressure adds ethanol and makes and contain alcohol amount and reach 65%, left standstill 12 hours, sucking filtration is got supernatant liquid filtering, filtrate is used ethyl acetate extraction 3 times, discards ethyl acetate liquid, combining water layer liquid, with hydrochloric acid adjust pH 3,, merge n-butyl alcohol liquid with water saturated n-butanol extraction 4 times, washing, reclaim under reduced pressure n-butyl alcohol, residue add 80% dissolve with ethanol, last polyamide column (500g, Φ 8cm, blade diameter length ratio 1: 6, absorption flow velocity 1.5BV/h), collect stream and wear liquid and eluent, reclaim ethanol, the residue vacuum drying gets the Herba Polygoni Orientalis extract;
Herba Erigerontis adds 10 times of decoctings and boils 3 times, each 0.5 hour, filters, merging filtrate, concentrating under reduced pressure adds ethanol and makes and contain alcohol amount and reach 55%, left standstill sucking filtration, decompression filtrate recycling ethanol and to be concentrated into relative density be 1.10 12 hours, with hydrochloric acid adjust pH to 2,55 ℃ are incubated 6 hours, the tipping supernatant, sucking filtration, precipitation washes with water to pH3-4, and microwave vacuum drying gets Herba Erigerontis extract;
Herba Polygoni Orientalis extract and Herba Erigerontis extract are merged, add 1800 milliliters of waters for injection, stir and make dissolving, add an amount of glycerol again, mixing, with saturated sodium carbonate adjust pH to 6.8～7.8, add water for injection to 10000 milliliter, filter with 0.45 μ m and 0.22 μ m microporous filter membrane, sterile filling, every 10ml sterilized 60 minutes down, promptly gets 1000 of compound oriental smartweed injection for 105 ℃.
Need to prove, more than only be to introduce a kind of method for preparing the method for extract and be prepared into ejection preparation, be in order to explain the present invention, rather than restriction the present invention.
Two, test example
1, the observation of treatment chronic glomerulonephritis curative effect
1.1 trial drug
The compound oriental smartweed injection, 10ml/ props up, and produces as stated above; Herba Erigerontis injection, 10ml/ props up, and Yunnan Biological Valley Breviscapin Pharmaceutical Co., Ltd. produces.
1.2 subjects and method
1.2.1 object is chosen 96 routine chronic glomerulonephritis patients, is internal medicine kidney district inpatient, compound oriental smartweed group, every group of each 48 example of Herba Erigerontis group.Male's 55 examples wherein, women's 41 examples; Age 25-70 year, 44.65 years old mean age; Course of disease 1-5; Blood pressure＜140/90mmHg, serum creatinine＜176.8 μ mol/L.
All continuous 2d surveyed the 24h urine protein quantitation when back and treatment finished 1.2.2 all patients of method are admitted to hospital, and got its meansigma methods, and to reduce testing error, the specimen censorship of hematuria is identical with urine protein.Under phase contrast microscope, calculate erythrocytic numerical value, and inspect blood examination simultaneously by ready samples, treating front and back each 1 time.Give Herba Erigerontis injection 40ml, compound oriental smartweed injection 40ml respectively, add 1 time/d of dilution posterior vein instillation among the 5% glucose injection 250ml, 2 weeks of the course of treatment.Do not use angiotensin converting enzyme inhibitor and other blood circulation promoting and blood stasis dispelling and platelet to separate synandrium, in order to avoid disturb the result.Diet control, rest etc., identical with the conventional therapy scheme.
, the statistical procedures data represent that adopt paired t-test, P＜0.05 is a significant difference 1.2.3 using X ± S.
1.3 result
1.3.1 urine protein changes before and after the treatment
Herba Erigerontis, compound oriental smartweed all have the effect of obvious reduction urine protein to the chronic glomerulonephritis patient.Result such as table 1:
Table 1 urine protein changes
| Group | Urine protein is turned out cloudy fully | Negative conversion rate (%) | Urine protein reduces more than 50% | Improvement rate (%) | The front and back no change | Inefficiency (%) |
| The Herba Erigerontis group | 13 | 27％ | 29 | 60％ | 6 | 12.5％ |
| The compound oriental smartweed group | 15 | 31％ | 29 | 60％ | 4 | 8.3％ |
The albuminuria patient 24h urine protein quantitation＜150mg/d that turns out cloudy fully, P＜0.05 relatively before and after each group and the treatment, significant difference; Compare there was no significant difference between each group.
1.3.2 the variation of hematuria before and after the treatment
Herba Erigerontis, compound oriental smartweed all have the effect of tangible reduction hematuria to the chronic glomerulonephritis patient, result such as table 2:
Table 2 hematuria changes
| Group | Hematuria is turned out cloudy fully | Negative conversion rate (%) | Hematuria reduces more than 50% | Improvement rate (%) | The front and back no change | Inefficiency (%) |
| The Herba Erigerontis group | 16 | 33％ | 28 | 58％ | 4 | 8.3％ |
| The compound oriental smartweed group | 15 | 31％ | 30 | 62.5％ | 3 | 6.2％ |
Hematuria patient counting＜0～3/HP that turns out cloudy fully, P＜0.05 relatively before and after the treatment, significant difference, P＜0.05 relatively before and after each group and the treatment, significant difference; Compare there was no significant difference between each group.
1.3.3 hemorheology index changes before and after the treatment
See Table 3.
Hemorheology index comparison before and after table 3 treatment (X ± S)
Annotate: relatively, P＜0.05 is compared in P＜0.01 between group before and after the treatment.
Urine protein, hematuria numerical value change before and after table 4 treatment
Annotate: compare P＜0.05 before and after the treatment, compare P＞0.05 between group.
1.5 conclusion
The chronic glomerulonephritis patient course of disease is long, state of an illness delay, hematuria and albuminuria long-term existence.After this is tested 96 routine chronic glomerulonephritis patients and uses Herba Erigerontis and quiet 14d of compound oriental smartweed respectively, compared remarkable decline before observing plasma viscosity, whole blood viscosity, whole blood reduced viscosity, Fibrinogen and treatment, the blood high viscosity and high coagulant state improves; Compare before urine protein and hematuria and the treatment, descend significantly, P＜0.05 illustrates that both all have the albuminuria that reduces the chronic glomerulonephritis patient and the effect of hematuria.But by data result as can be known compound oriental smartweed group curative effect illustrate that a little more than the Herba Erigerontis group compound recipe is better than folk prescription, reached the effect of Synergistic.
2, to the effect of rat test nephropathy urine protein
2.1 trial drug and reagent
The compound oriental smartweed injection, 10ml/ props up; Herba Erigerontis injection, 10ml/ props up, and Yunnan Biological Valley Breviscapin Pharmaceutical Co., Ltd. produces; Radix Astragali injection, 10ml/ props up, Chengdu Diao 9 Wang pharmaceutical factory production; Doxorubicin hydrochloride, 10mg/ props up, the production of Mingzhi's medicine company limited; Albumin standards, 40mg/ml, Beijing Zhongsheng Biological Engineering High Technology Company produces.
2.2 experimental animal: the Wistar rat, male, body weight 170～190g, the Guiyang Medical College Experimental Animal Center provides.
2.3 test method
2.3.1 model preparation and grouping: male 6 age in week 50 of Wistar rats, body weight 180 ± 10g is divided into 5 groups at random: physiology matched group, model control group, Herba Polygoni Orientalis group, Radix Astragali group and Herba Erigerontis group.Except that the physiology matched group, all the other respectively organize rat tail vein injection amycin 7mg/kg, and normal saline group intravenous injection normal saline 0.2ml/ only.When injection back 2 all urine protein are obvious, begin treatment intraperitoneal injection 42d, medicining condition: lumbar injection Herba Polygoni Orientalis group 0.4mlkg
-1D
-1, Radix Astragali group: 0.4mlkg
-1D
-1, Herba Erigerontis group 0.24mlkg
-1D
-1, each lumbar injection capacity is general＜and 1.0ml/ is only; Physiology matched group and model control group: every day every intraperitoneal injection of saline 0.5ml.
2.3.2 observation index and method: the mensuration of urine protein: the intravenous injection amycin is preceding and the 2nd, 4,6,8 weeks collected the 24h urines of animals, and adopts the bromophenol blue method that urine protein is carried out quantitative assay.
2.3.3 statistical procedures: all measurement results are with (relatively with the t check, treatment group and model group adopt variance analysis more at one time for x ± s) expression, model group and physiology matched group.
2.4 result
2.4.1 ordinary circumstance: symptoms such as behind the intravenous injection amycin, rat lassitude occurs, shrink, movablely reduce, appetite descends, loses weight, about 70% rat has the alopecia areata depilation.The time that Herba Polygoni Orientalis group depilation takes place is later, and the time that grows virgin wool again early better.In about 2 whens week behind the intravenous injection amycin, eye discharge appears in 40% rat to be increased, and part rat eye discharge slowly solidifies and forms the White-opalescent incrustation, occurs one-sided or bilateral loses one's sight.The intravenous injection amycin is in the time of the 15th day, and model group, Herba Polygoni Orientalis group, Radix Astragali group and Herba Erigerontis group are lost the sight of both eyes the Mus number and be respectively 3,1,1,2, and monocular is blind to be respectively 4,2,2,2.Experimental session has 12 death for the rat of amycin, and wherein model control group is 5,2 of Herba Polygoni Orientalis groups, 2 of Radix Astragali groups, 3 of Herba Erigerontis groups.Compare with model control group, the case fatality rate of Herba Polygoni Orientalis group rat is lower; It is very fast that the mental status of Herba Polygoni Orientalis group rat is recovered very fast, movable recovery more, body weight.Each is organized the rat body weight variation and sees Table 5.
Respectively organize rat body weight behind the table 5 intravenous injection amycin and change (x ± s)
Annotate: * and saline group be P＜0.01 relatively; # and model group be P＜0.05 relatively
2.4.2 urine protein: test preceding 50 rat 24h urine protein outputs all＜20mg, rat all occurs tangible albuminuria in the intravenous injection amycin after 2 weeks.Each is organized rat 24h urine protein output and dynamic observes and see Table 6.8 weeks behind the intravenous injection amycin, model control group rat 24h urine protein output average out to 381mg; Herba Polygoni Orientalis group, Radix Astragali group, Herba Asari group are respectively 173.4mg (P＜0.05), 183mg (P＜0.05) and 247mg (P＜0.05), have reduced 54.5%, 52.0% and 35.2% more respectively with model control group.
Respectively organize rat 24h urine protein output (x ± s) behind the table 6 intravenous injection amycin
Annotate: compare * P＜0.01 with model control group; #P＜0.05
2.5 conclusion
Nephrotic syndrome is one group of sings and symptoms that multiple renal glomerular disease causes.This experiment adopts rat disposable vein injection amycin 7mg/kg to make animal nephrotic syndrome model.Rat behind the quiet notes serious albuminuria all occurred after 2 weeks, and 24h urine protein output obviously increases, the 8th weekend average out to 381mg.Significantly reduce with the 24h urine protein output of model control group comparison Herba Polygoni Orientalis group, Radix Astragali group, Herba Asari group rat, can find out that by experimental data Herba Polygoni Orientalis group therapeutic equivalence in Radix Astragali group, is better than the Herba Erigerontis group.Show that the pharmacodynamics effect behind the prescription obviously strengthens, compound recipe is better than folk prescription.
3, to the protective effect of the obstructive kidney region fibrosis of rat
3.1 trial drug and reagent
The compound oriental smartweed injection, 10ml/ props up; Radix Salviae Miltiorrhizae Injection 10ml/ props up, and Shanghai first pharmaceutical factory produces.
3.2 experimental animal: the SD rat, female, body weight 260280g, the Guiyang Medical College Experimental Animal Center provides.
3.3 test method
3.3.1 model preparation and grouping: 40 of SD rats are divided at random: matched group, modeling group, compound oriental smartweed group and Radix Salviae Miltiorrhizae group, every group each 10.With pentobarbital sodium 45mg/kg intraperitoneal injection of anesthesia rat, row left side ligation of ureter.Matched group only finds not ligation of ureter.24h compound oriental smartweed group rat gives 0.4mlkg before operation
-1D
-1, the Radix Salviae Miltiorrhizae group gives 0.8mlkg
-1D
-1, lumbar injection.Contrast and modeling group are given the normal saline of equivalent.
3.3.2 test item and method
With each group rat sacrificed by decapitation, half placed 10% formalin fixed liquid to get art side nephridial tissue, makes pathology section and immunohistochemical staining ureteral obstruction postoperative the 10th day, and second half places the freezing preservation of liquid nitrogen, detected in order to making RT-PCR.
The pathological change of matter between renal tubules: with the nephridial tissue routine paraffin wax embedded section of 10% formalin fixed, after HE, PAS dyeing, light microscopic is observed interstitial disease of renal tubule down; Immunohistochemistry detects: adopt the SABC method; TGF-β
1MRNA measures.
3.3.3 statistical method: all data adopt all that (expression of x ± s), group difference are relatively with t check or variance analysis.
3.4 result
3.4.1 the pathological change of matter: HE and PAS dyeing shows between renal tubules, 10d behind UUO, modeling group and treatment group rat block that side nephridial tissue visible part renal tubules is expanded in various degree, necrosis, a large amount of monokaryons and lymphocytic infiltration, matter district enlarged areas between tubule, tubule cell based counterdie ruptures in various degree and thickens, and glomerule changes not obvious; Matched group kidney structure is normal.See Table 7.
Table 7 respectively organize kidney of rats cortex relatively between matter volume (x ± s)
| Group | The example number | Matter volume (%) relatively |
| Matched group | 10 | 13.82±1.24 |
| The modeling group | 10 | 27.36±0.60* |
| The compound oriental smartweed group | 10 | 26.33±0.60*△ |
| The Radix Salviae Miltiorrhizae group | 10 | 26.38±0.60*△ |
Annotate: compare * P＜0.01 with matched group; Compare △ P＜0.01 with the modeling group
3.4.2 immuning tissue's coloration result
3.4.2.1TGF-β 1 dyeing: in normal kidney, a small amount of TGF-β 1 positive staining comes across in the renal cells endochylema, does not almost have expression in the glomerule.
3.4.2.2 α-SMA dyeing: A organizes demonstration, and α-SMA only expresses on the normal kidney tissue blood vessel wall, does not have positive dyeing in bead and the tubule; B group and C group have on blood vessel wall the expression, and visible a large amount of positive cells appears in the interstitial cell endochylema, the positive staining granule also occurs in the part tubule epithelial cell endochylema simultaneously.Each is organized does not all have obvious α-SMA positive staining in the kidney of rats bead.
3.4.2.3I Collagen Type VI dyeing: A organizes demonstration, type i collagen only has a small amount of expression in the matter between kidney, does not have positive dyeing in little solencyte and the bead.See Table 8.
Table 8 is respectively organized rat immunity group semiquantitative determination value (x ± s)
| Group | The example number | TGFβ1(％) | αSMA(％) | Type i collagen (%) |
| Matched group | 10 | 2.75±0.84 | 0.44±0.03 | 4.92±0.25 |
| The modeling group | 10 | 11.37±0.72* | 16.55±0.64* | 16.55±0.61* |
| The compound oriental smartweed group | 10 | 6.88±1.10*△△ | 15.36±0.57* | 13.7±0.64*△△ |
| The Radix Salviae Miltiorrhizae group | 10 | 6.75±1.06*△△ | 15.21±0.51*△ | 13.47±0.7*△△ |
Annotate: compare * P＜0.01 with matched group; Compare △ P＜0.05, △ △ P＜0.01 with the modeling group
3.4.3TGF-β
1MRNA measurement result: matched group renal cortex TGF-β
1The only faint expression of mRNA, 10d modeling group Ren Mus cortex TGF-β 1mRNA expresses obviously raise (comparing P＜0.01 with the A group), compound oriental smartweed and Radix Salviae Miltiorrhizae group TGF-β behind the UUO
1MRNA expresses than modeling group obviously low (P＜0.01), than matched group rising (P＜0.05).See Table 9.
Table 9 is respectively organized kidney of rats cortex TGF-β 1mRNA relative optical density value
| Group | The example number | TGF-β1mRNA |
| Matched group | 3 | 3.48±0.30 |
| The modeling group | 3 | 6.57±0.24** |
| The compound oriental smartweed group | 3 | 4.36±0.51*△ |
| The Radix Salviae Miltiorrhizae group | 3 | 4.31±0.44*△ |
Annotate: compare * P＜0.05, * * P＜0.01 with matched group; Compare △ P＜0.01 with the modeling group
3.5 conclusion
Phenotype transforms and plays an important role in the kidney region fibrosis pathogenesis, above experimental result shows, the Herba Polygoni Orientalis compositions can suppress the tubule Interstitial cell and transform to myofibroblast, play the effect that delays kidney region fibrosis, can reduce the content of kidney cortex IV Collagen Type VI and laminin due to the amycin rat, alleviate caused by doxorubicin glomerular sclerosis degree.Its action effect and Radix Salviae Miltiorrhizae Injection relatively do not have significant difference, show that curative effect and Radix Salviae Miltiorrhizae Injection are suitable.
Confirm by above a series of animal experiment: Herba Polygoni Orientalis compositions of the present invention can be treated kidney disease, seroimmunity nephritis rat model kidney weight is increased, increased platelets counts number and leukocyte count, reduce liquor-saturated, the urea nitrogen content of serum flesh, improve seroimmunity nephritis renal insufficiency kidney of rats function; Can strengthen renal tubular cell and decompose proteinic effect in the urine, reduce caused by doxorubicin albuminuria level; Can reduce simultaneously the content of amycin rat kidney cortex IV Collagen Type VI and laminin, alleviate the glomerular sclerosis degree, delay the generation of kidney region fibrosis.Use Herba Polygoni Orientalis compositions of the present invention the therapeutical effect of nephrotic syndrome and chronic renal insufficiency almost to be equivalent to use separately the therapeutical effect of the Radix Astragali and Radix Salviae Miltiorrhizae separately, and curative effect is better than using separately Herba Erigerontis injection, show that the pharmacodynamics effect behind the prescription obviously strengthens, compound recipe is better than folk prescription.
Compared with prior art, the invention provides a kind of new medical usage of Herba Polygoni Orientalis and erigeron breviscapus composition, be the application of said composition aspect preparation treatment kidney disease medicine, and confirmed that by animal experiment Herba Polygoni Orientalis and erigeron breviscapus composition have definite curative effect to the treatment of kidney disease, for the treatment of kidney disease provides a kind of new medicine,, the patient selects for providing a kind of new medication.
The specific embodiment
This preparation embodiment introduces a kind of preparation method for compositions, is in order to explain the present invention, rather than restriction the present invention.
Embodiment 1: the preparation of injection
Raw material: Herba Polygoni Orientalis 7500g, Herba Erigerontis 1500g
Preparation method: get Herba Polygoni Orientalis and add 10 times of decoctings and boil 3 times, each 1 hour, filter, merging filtrate, concentrating under reduced pressure adds ethanol and makes and contain alcohol amount and reach 65%, left standstill 12 hours, sucking filtration is got supernatant liquid filtering, filtrate is used ethyl acetate extraction 3 times, discards ethyl acetate liquid, combining water layer liquid, with hydrochloric acid adjust pH 3,, merge n-butyl alcohol liquid with water saturated n-butanol extraction 4 times, washing, reclaim under reduced pressure n-butyl alcohol, residue add 80% dissolve with ethanol, last polyamide column (500g, Φ 8cm, blade diameter length ratio 1: 6, absorption flow velocity 1.5BV/h), collect stream and wear liquid and eluent, reclaim ethanol, the residue vacuum drying gets the Herba Polygoni Orientalis extract;
Herba Erigerontis adds 10 times of decoctings and boils 3 times, each 0.5 hour, filters, merging filtrate, concentrating under reduced pressure adds ethanol and makes and contain alcohol amount and reach 55%, left standstill sucking filtration, decompression filtrate recycling ethanol and to be concentrated into relative density be 1.10 12 hours, with hydrochloric acid adjust pH to 2,55 ℃ are incubated 6 hours, the tipping supernatant, sucking filtration, precipitation washes with water to pH3-4, and microwave vacuum drying gets Herba Erigerontis extract;
Herba Polygoni Orientalis extract and Herba Erigerontis extract are merged, add 1800 milliliters of waters for injection, stir and make dissolving, add an amount of glycerol again, mixing, with saturated sodium carbonate adjust pH to 6.8～7.8, add water for injection to 10000 milliliter, filter with 0.45 μ m and 0.22 μ m microporous filter membrane, sterile filling, every 10ml sterilized 60 minutes down, promptly gets 1000 of compound oriental smartweed injection for 105 ℃.Kidney disease there is definite curative effect.
The consumption of injection: 60mg crude drug/kg body weight/day.Kidney disease there is definite curative effect.
Embodiment 2: the preparation of tablet
Raw material: Herba Polygoni Orientalis 1000g, Herba Erigerontis 5000g
Preparation method: get Herba Polygoni Orientalis, add 4 times of water gagings and decoct once, decocted 0.5 hour, filter, merging filtrate, being evaporated to relative density is 1.05 (50 ℃), add ethanol and make and contain alcohol amount and reach 20%, stir, left standstill 6 hours, sucking filtration, decompression filtrate recycling ethanol also is concentrated into relative density 1.04 (50 ℃), with saturated sodium carbonate adjust pH to 4.7, fully stir, left standstill 1 hour, and got supernatant and filter, filtrate is with the ethyl acetate extraction of 1/4 times of amount 1 time, discard ethyl acetate liquid, combining water layer liquid is with hydrochloric acid adjust pH to 1, with the saturated n-butanol extraction of 1/4 times of water gaging 2 times, merge n-butyl alcohol liquid, wash 1 time with 1/16 times of water gaging, reclaim under reduced pressure n-butyl alcohol, residue add 45% dissolve with ethanol, last polyamide column (10g, diameter 4cm, blade diameter length ratio 1: 2, absorption flow velocity: 0.5BV/h), collect stream and wear liquid and eluent, reclaim ethanol, the residue vacuum drying gets the Herba Polygoni Orientalis extract;
Herba Erigerontis adds 4 times of water gagings and decocts 1 time, each 0.2 hour, filters, merging filtrate, being evaporated to relative density is 1.09 (50 ℃), adds ethanol and makes and contain alcohol amount and reach 20%, constantly stir, left standstill sucking filtration 6 hours, decompression filtrate recycling ethanol also is concentrated into relative density 1.10 (50 ℃), and with hydrochloric acid adjust pH to 1,55 ℃ are incubated 2 hours, the tipping supernatant, sucking filtration, precipitation washes with water to pH value to 2, vacuum drying gets Herba Erigerontis extract;
Get Herba Polygoni Orientalis extract and Herba Erigerontis extract, mix homogeneously adds adjuvant, granulate, and tabletting, promptly.
Usage and dosage: oral, 50mg crude drug/kg body weight/day.Kidney disease there is definite curative effect.
Embodiment 3: the preparation of capsule
Get Herba Polygoni Orientalis 100g and Herba Erigerontis 1000g, pulverize, mixing decocts with water, and filters, and filtrate decompression is condensed into extractum, adds the conventional adjuvant of capsule, and preparation process prepares capsule routinely.
Usage and dosage: oral: 75mg crude drug/kg body weight/day.Kidney disease there is definite curative effect.
Embodiment 4: the preparation of granule
Get Herba Polygoni Orientalis 1000g and Herba Erigerontis 100g, pulverize mixing, decoct with water, filter, filtrate decompression is condensed into extractum, handles with ethanol precipitation, decompression recycling ethanol, adjust pH is placed to neutral, get the supernatant ethyl acetate extraction, water layer liquid adjust pH is used n-butanol extraction to acid, the reclaim under reduced pressure n-butyl alcohol, the residue dissolve with ethanol, polyamide column separates, the ethanol elution with 50～95%, collect stream and wear liquid and eluent, reclaim ethanol, the residue vacuum drying gets Herba Polygoni Orientalis and Herba Erigerontis mixed extract, adds ethanol system soft material, granulate, drying, packing gets granule.
Usage and dosage: take after mixing it with water 40mg crude drug/kg body weight/day.Kidney disease there is definite curative effect.
Embodiment 5: Herba Polygoni Orientalis and Herba Erigerontis extract with obtaining in embodiment 1,2,3 or 4 are prepared into pill with the galenic pharmacy routine techniques.
Embodiment 6: routine is extracted (decocting in water precipitate with ethanol or alcohol reflux extract refining) Herba Polygoni Orientalis extract and Herba Erigerontis extract that method obtains, be prepared into suspending agent or Emulsion with the galenic pharmacy routine techniques.
Embodiment 7: Herba Polygoni Orientalis extract and Herba Erigerontis extract that embodiment 1 is obtained mix, and are prepared into infusion solution with the galenic pharmacy routine techniques.
Embodiment 7: Herba Polygoni Orientalis and Herba Erigerontis extract with embodiment 1,2,3,4 or 6 obtains are prepared into lyophilized injectable powder with the galenic pharmacy routine techniques.
Claims (10)
1. Herba Polygoni Orientalis and the erigeron breviscapus composition application in preparation treatment kidney disease medicine.
2. Herba Polygoni Orientalis and the erigeron breviscapus composition application in preparation treatment nephritis medicine.
3. Herba Polygoni Orientalis and the erigeron breviscapus composition application in preparation treatment nephrotic syndrome medicine.
4. Herba Polygoni Orientalis and the erigeron breviscapus composition application in preparation treatment chronic renal failure medicine.
5. Herba Polygoni Orientalis and the erigeron breviscapus composition application in preparation treatment medicine for treating diabetic nephropathy.
6. Herba Polygoni Orientalis and the erigeron breviscapus composition application in preparation treatment chronic glomerulonephritis medicine.
7. according to the application in the preparation medicine of the arbitrary described Herba Polygoni Orientalis of claim 1-6 and erigeron breviscapus composition, it is characterized in that: described Herba Polygoni Orientalis and erigeron breviscapus composition merge the back by raw material of Chinese medicine Herba Polygoni Orientalis and Herba Erigerontis and extract the extract of gained or extract the extract that the back merges gained respectively and form.
8. the application in the preparation medicine according to described Herba Polygoni Orientalis of claim 7 and erigeron breviscapus composition, it is characterized in that: according to listed as parts by weight, described Herba Polygoni Orientalis and erigeron breviscapus composition are to be prepared from through extraction for 1～10 part by 1～10 part of raw material of Chinese medicine Herba Polygoni Orientalis and Herba Erigerontis.
9. the application in the preparation medicine according to arbitrary described Herba Polygoni Orientalis of claim 1-6 and erigeron breviscapus composition, it is characterized in that: described medicine is ejection preparation, tablet, pill, capsule, granule, suspending agent or Emulsion.
10. the application in the preparation medicine according to described Herba Polygoni Orientalis of claim 9 and erigeron breviscapus composition, it is characterized in that: described medicine is an ejection preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008103025306A CN101306091B (en) | 2008-07-04 | 2008-07-04 | Use of prince feather and fleabane combination in preparing medicament for treating kidney disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008103025306A CN101306091B (en) | 2008-07-04 | 2008-07-04 | Use of prince feather and fleabane combination in preparing medicament for treating kidney disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101306091A true CN101306091A (en) | 2008-11-19 |
| CN101306091B CN101306091B (en) | 2011-02-02 |
Family
ID=40122927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008103025306A Expired - Fee Related CN101306091B (en) | 2008-07-04 | 2008-07-04 | Use of prince feather and fleabane combination in preparing medicament for treating kidney disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101306091B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757129B (en) * | 2008-12-26 | 2011-10-26 | 贵州益佰制药股份有限公司 | Composition preparation containing orientin and isoorientin and preparation method thereof |
| CN101732443B (en) * | 2008-11-26 | 2012-01-11 | 贵州益佰制药股份有限公司 | Application of Herba Polygoni Orientalis-containing composition in preparation of medicaments of treating kidney diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1194724C (en) * | 2002-12-19 | 2005-03-30 | 姚茂荣 | Chinese medical preparation for treating coronary disease and angina pectoris and preparation thereof |
-
2008
- 2008-07-04 CN CN2008103025306A patent/CN101306091B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732443B (en) * | 2008-11-26 | 2012-01-11 | 贵州益佰制药股份有限公司 | Application of Herba Polygoni Orientalis-containing composition in preparation of medicaments of treating kidney diseases |
| CN101757129B (en) * | 2008-12-26 | 2011-10-26 | 贵州益佰制药股份有限公司 | Composition preparation containing orientin and isoorientin and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101306091B (en) | 2011-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102908583B (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition | |
| CN104645132A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy, preparation method, traditional Chinese medicine preparation and application of traditional Chinese medicine composition | |
| CN103191204B (en) | Medicine composite for treating chronic kidney diseases and preparation method and application of medicine composite | |
| CN104173503B (en) | The Chinese herbal granules of the preparation method of a kind of Chinese herbal granules and preparation thereof and purposes | |
| CN101306091B (en) | Use of prince feather and fleabane combination in preparing medicament for treating kidney disease | |
| CN102475765B (en) | Traditional Chinese medicine composition for improving renal functions and restraining renal fibrosis | |
| CN107149631A (en) | A kind of method for separating and preparing of Kwangtung purple beautyberry extract and application thereof | |
| CN103893283A (en) | Traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method and use | |
| CN106310017B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung and kidney qi deficiency syndrome | |
| CN101700265A (en) | Application of pseudo-ginseng and extract thereof in preparing medicament for curing and/or preventing diabetic microangiopathies | |
| CN104161850A (en) | Preparation method of Chinese herbal extract, prepared Chinese herbal extract and application | |
| CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN101732443B (en) | Application of Herba Polygoni Orientalis-containing composition in preparation of medicaments of treating kidney diseases | |
| CN102861192B (en) | Medicine composition for chronic renal failure and peritoneal fibrosis | |
| CN103877327A (en) | Pharmaceutical composition for treating nephritic syndrome, as well as preparation method and applications thereof | |
| CN101632780B (en) | Application of Chinese medicinal composition in preparing medicament for treating diabetic nephropathy | |
| CN104352962A (en) | Medicinal composition for treating renal fibrosis, as well as preparation method and application thereof | |
| CN103893286A (en) | Traditional Chinese medicinal preparation for treating chronic renal disease and preparation method thereof | |
| CN103446494B (en) | Chinese patent medicine for treating Type II diabetic nephropathy and preparation method thereof | |
| CN102119960A (en) | Medicinal composition for activating blood, dissolving stasis, tonifying qi and freeing vessels | |
| CN102078367B (en) | Use of aidi preparation in preparation of medicaments for treating multiple organ dysfunction syndrome in elderly | |
| CN100443093C (en) | AIDS treating medicine | |
| CN103735901A (en) | Diuretic and anti-inflammatory traditional Chinese medicine composition and preparation method thereof | |
| CN103655909A (en) | Application of compound thrombosis capsule in aspect of kidney protection | |
| CN105288410A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110202 Termination date: 20140704 |
|
| EXPY | Termination of patent right or utility model |